KBL Healthcare Ventures

Dr. Marlene Krauss, the firm's founder and a practicing cardiologist, leads the investment committee. She is supported by Partner Zachary Berk and a dedicated team of investment professionals, many of whom bring operating or clinical backgrounds to the diligence process. Final decisions rest with Dr. Krauss and the senior partnership.

KBL's sourcing network is built on Dr. Krauss's clinical relationships, academic medical center connections, and a track record that dates to 1991. The firm evaluates technologies based on their ability to solve real clinical workflow problems or improve patient outcomes, not purely on market size or reimbursement arbitrage. Its LPs include academic medical centers, which further extends its clinical reference network.

The firm concentrates on seed and Series A healthcare rounds, with reserves for follow-on participation through growth stages. While precise check sizes are not publicly disclosed, KBL's $195 million fourth fund suggests initial commitments in the $5 million to $15 million range, scaled appropriately for early-stage device, biotech, and services companies seeking FDA clearance or initial commercialization.

Yes. KBL sponsors KBL Merger Corp. IV, a special purpose acquisition company (SPAC) targeting healthcare businesses. This vehicle allows the firm to participate in larger transactions and public-market transitions that fall outside its traditional early-stage venture fund mandate. As of late 2023, KBL Merger Corp. IV announced a business combination with 180 Life Sciences Corp.

KBL has not publicly disclosed exclusionary criteria, but its investment history skews toward therapeutic areas and medical devices with regulatory-moat potential. The firm's physician-led diligence process tends to favor interventions with quantifiable clinical endpoints rather than pure wellness, consumer health, or non-regulated digital health apps.

The KBL brand encompasses both the venture capital limited partnerships (KBL Healthcare Ventures I–IV) and the SPAC vehicles (KBL Merger Corp. I–IV). Both are managed by the same core team under Dr. Krauss's leadership, with the venture funds targeting private early-stage investments and the SPACs targeting larger, later-stage healthcare acquisitions suitable for public listing.

KBL's LP base includes traditional institutional investors — endowments, foundations, and pension funds — alongside academic medical centers and physician-investor networks. This clinical LP composition is unusual among healthcare venture firms and reinforces the firm's credibility when evaluating and de-risking novel medical technologies.